Molecular Partners Ag (MOLN) Interest Expenses (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest Expenses of -$14.05 for Q1 2026, up 98.88% year-over-year from -$7.06 in Q1 2025, and down 100.0% quarter-over-quarter from $6.3 million in Q4 2025.
Molecular Partners Ag (MOLN) Interest Expenses (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest Expenses for 7 consecutive years, with -$14.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 98.88% year-over-year to -$14.05; the TTM figure through Mar 2026 stood at $10.5 million (up 17729.92% YoY), while the FY2025 annual figure was $6.3 million, up 14457.33% from the prior year.
- Interest Expenses fell to -$14.05 in Q1 2026 per MOLN's latest filing, from $6.3 million in the prior quarter.
- Across five years, Interest Expenses topped out at $6.3 million in Q4 2025 and bottomed at -$2923.6 in Q3 2024.
- Historically, Interest Expenses has averaged $1.1 million across 5 years, with a median of $269.62 in 2022.
- Annual changes were most pronounced in 2024 — Interest Expenses sank 23375.85% — and 2025, when it surged 21145.8%.
- Molecular Partners Ag's Interest Expenses stood at $671192.2 in 2022, then surged by 765.85% to $5.8 million in 2023, then plunged by 99.25% to $43410.9 in 2024, then jumped by 14446.26% to $6.3 million in 2025, then tumbled by 100.0% to -$14.05 in 2026.
- Business Quant data shows MOLN's Interest Expenses at -$14.05 in Q1 2026, $6.3 million in Q4 2025, and -$196.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -14.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.05 |
| Mar 31, 2026 | -14.05 |
| Dec 31, 2025 | 6.31 Mn |
| Dec 31, 2025 | 6.31 Mn |
| Sep 30, 2025 | -196.27 |
| Sep 30, 2025 | -196.27 |
| Jun 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | -1,259.07 |
| Mar 31, 2025 | -1,259.07 |
| Dec 31, 2024 | 43,410.93 |
| Dec 31, 2024 | 43,410.93 |
| Sep 30, 2024 | -2,923.61 |
| Sep 30, 2024 | -2,923.61 |
| Jun 30, 2024 | 19,904.28 |
| Jun 30, 2024 | 19,904.28 |
| Mar 31, 2024 | -11.46 |
| Mar 31, 2024 | -11.46 |
| Dec 31, 2023 | 5.81 Mn |
| Dec 31, 2023 | 5.81 Mn |